The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Omega-3 fatty acids in health and disease and in growth and development.
Simopoulos, A. (1991) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/54.3.438 · Cited by 2,162
Jablensky, A., Sartorius, N., Ernberg, G., Anker, M., Korten, A., Cooper, J. E., Day, R., & Bertelsen, A. (1992) · Psychological Medicine. Monograph Supplement · doi:10.1017/s0264180100000904 · Cited by 1,769
Defining the phenotype of schizophrenia: cognitive dysmetria and its neural mechanisms
Andreasen, N. C., Nopoulos, P., O’Leary, D. S., Miller, D. D., Wassink, T., & Flaum, M. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00152-3 · Cited by 560
Peet, M., Brind, J., Ramchand, C. N., Shah, S., & Vankar, G. K. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00083-9 · Cited by 329 · cited 2×
“The procedure for fatty acid analysis used in our study was revised from the original method of Manku et al (1983) and has been used in several recent reports (Mahadik et al 1996; Peet et al 1996, 2001 ).”
BackgroundMethod
Research works printed but not linked: 56
- Arvindakshan M (2002): The Role of Membrane Essential Polyunsaturated Fatty Acids in Schizophrenia Outcome. Pune, India: Pune University Press
- Arvindakshan M, Ghate M, Ranjekar PK, Evans DR, Mahadik SP (in press): Supplementation with a combination of ω-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophr Res · DOI · Paper page
- Assies, 2001, Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group, Biol Psychiatry, 49, 510, 10.1016/S0006-3223(00)00986-0 · DOI · Paper page
- Axelrod, 1990, Receptor-mediated activation of phospholipase A2 and arachidonic acid release in signal transduction, Biochem Soc Trans, 18, 503, 10.1042/bst0180503 · doi:10.1042/bst0180503
- Bloom, 1993, Advancing a neurodevelopmental origin for schizophrenia, Arch Gen Psychiatry, 50, 224, 10.1001/archpsyc.1993.01820150074008 · DOI · Paper page
- Cadet, 1987, Free radicals and the developmental pathophysiology of schizophrenia burnout, Integr Psychiatry, 5, 40
- Carlson, 1986, High fat diets varying ratios of polyunsaturated to saturated fatty acids and linolenic acid, a comparison of rat neural and red cell membrane phospholipids, J Nutr, 116, 718, 10.1093/jn/116.5.718 · DOI · Paper page
- Carpenter, 1988, Deficit and non-deficit forms of schizophrenia, Am J Psychiatry, 145, 578, 10.1176/ajp.145.5.578 · DOI · Paper page
- Evans, 2001, Cell membrane essential fatty acid status in drug-naïve first-episode psychotic patients and its relation to outcome, Schizophr Res, 49, 83
- Fenton, 2001, A placebo-controlled trial of omega-3 fatty acids (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia, Am J Psychiatry, 158, 2071, 10.1176/appi.ajp.158.12.2071 · DOI · Paper page
- Fenton, 2000, Essential fatty acids, lipid membrane abnormalities, and the diagnosis of schizophrenia, Biol Psychiatry, 47, 8, 10.1016/S0006-3223(99)00092-X · DOI · Paper page
- Fujimoto, 1992, Study of chronic schizophrenics using 31P magnetic resonance chemical shift imaging, Acta Psychiatr Scand, 86, 455, 10.1111/j.1600-0447.1992.tb03297.x · DOI
- Fukuzako, 1996, Phosphorus magnetic resonance spectroscopy in schizophrenia, Progr Neuropsychopharmacol Biol Psychiatry, 20, 629, 10.1016/0278-5846(96)00036-X · DOI
- Gattaz, 1990, Increased serum phospholipase A2 activity in schizophrenia, Biol Psychiatry, 28, 495
- Glen, 1994, A red cell membrane abnormality in a subgroup of schizophrenic patients, Schizophr Res, 12, 53, 10.1016/0920-9964(94)90084-1 · DOI · Paper page
- Horrobin, 1996, Schizophrenia as a membrane lipid disorder, which is expressed throughout the body, Prostaglandin Leukotr Essent Fatty Acids, 55, 3, 10.1016/S0952-3278(96)90138-6 · DOI
- Horrobin, 1998, The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia, Schizophr Res, 30, 193, 10.1016/S0920-9964(97)00151-5 · DOI · Paper page
- Horrobin, 1994, The membrane hypothesis of schizophrenia, Schizophr Res, 13, 195, 10.1016/0920-9964(94)90043-4 · DOI · Paper page
- Horrobin, 1991, Fatty acid levels in the brains of schizophrenics and normal control subjects, Biol Psychiatry, 30, 795, 10.1016/0006-3223(91)90235-E · DOI · Paper page
- Hudson, 1996, Genetic variant near cytosolic phospholipase A2 associated with schizophrenia, Schizophr Res, 21, 111, 10.1016/0920-9964(96)00031-X · DOI
- Hudson, 1993, CNS signal transduction and pathophysiology and pharmacotherapy of affective disorder and schizophrenia, Synapse, 13, 278, 10.1002/syn.890130311 · DOI
- Jedding, 1995, Characterization of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs, Biochem Pharmacol, 49, 359, 10.1016/0006-2952(94)00424-K · DOI
- Joffe, 1998, Is there an association between the effects of clozapine on the production of reactive oxygen metabolites by blood monocytes and clinical outcome in neuroleptic-resistant schizophrenia?, Schizophr Res, 29, 172, 10.1016/S0920-9964(97)88746-4 · doi:10.1016/s0920-9964(97)88746-4
- Katila, 1997, No differences in phospholipase-A2 activity between acute psychiatric patients and control subjects, Schizophr Res, 26, 103, 10.1016/S0920-9964(97)00054-6 · doi:10.1016/s0920-9964(97)00054-6
- Keshavan, 1993, Erythrocyte membrane phospholipids in psychotic patients, Psychiatry Res, 49, 89, 10.1016/0165-1781(93)90032-C · DOI
- Keshavan, 1993, Frontal lobe metabolism & cerebral morphology in schizophrenics, Schizophr Res, 10, 241, 10.1016/0920-9964(93)90058-Q · DOI
- Khan MM, Evans DR, Gunna V, Scheffer RE, Parikh VV, Mahadik SP (in press): Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr Res · DOI · Paper page
- Konings, 1979, Radiation effects on membranes I, Radiation Res, 80, 494, 10.2307/3574991 · DOI
- Kramer, 1987, The effects of ischemia and recirculation, hypoxia and recovery on antioxidant factors and α-adrenoreceptor density, Biochem Biophys Res Commun, 149, 568, 10.1016/0006-291X(87)90405-0 · DOI
- Mahadik, 2001, Oxidative stress and role of antioxidant and −3 essential fatty acid supplementation in schizophrenia, Progr Neuropsychopharmacol Biol Psychiatry, 25, 263, 10.1016/S0278-5846(00)00181-0 · DOI · Paper page
- Mahadik, 1996, Free radical pathology and antioxidant defense in schizophrenia, Schizophr Res, 19, 1, 10.1016/0920-9964(95)00049-6 · DOI · Paper page
- Mahadik, 1994, Plasma membrane phospholipid and cholesterol distribution of skin fibroblasts from drug-naïve patients at the onset of psychosis, Schizophr Res, 13, 239, 10.1016/0920-9964(94)90048-5 · DOI
- Mahadik, 1996, Plasma membrane phospholipid fatty acid composition of cultured skin fibroblasts from schizophrenic patients, Psychiatry Res, 63, 133, 10.1016/0165-1781(96)02899-5 · DOI
- Mahadik, 1998, Elevated plasma lipid peroxides at the onset of nonaffective psychosis, Biol Psychiatry, 43, 674, 10.1016/S0006-3223(97)00282-5 · DOI · Paper page
- Manku MS, Horrobin DF, Huang S, Morse N (1983): Fatty acids in plasma and red cell membranes. Lipids 18:906–908. · DOI · Paper page
- McCreadie, 1995, The Nithsdale Schizophrenia Surveys. XIV. Plasma lipid peroxide and serum vitamin E levels in patients with and without tardive dyskinesia, and in normal subjects, Br J Psychiatry, 167, 610, 10.1192/bjp.167.5.610 · DOI
- Nasrallah, 1993, Neurodevelopmental pathogenesis of schizophrenia, Psychiatr Clin North Am, 16, 269, 10.1016/S0193-953X(18)30173-4 · DOI
- Neuringer, 1986, Biochemical and functional effects of prenatal and post-natal ω-3 fatty acid deficiency on retina and brain in rhesus monkeys, Proc Natl Acad Sci U S A, 83, 4021, 10.1073/pnas.83.11.4021 · DOI · Paper page
- Peet, 2002, A dose ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms, J Psychiatric Res, 36, 7, 10.1016/S0022-3956(01)00048-6 · DOI · Paper page
- Peet, 1995, Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients, J Psychiatr Res, 29, 227, 10.1016/0022-3956(95)00001-L · DOI
- Peet, 1996, Essential fatty acid deficiency in erythrocyte membranes from chronic schizophrenic patients and the clinical effects of dietary supplementation, Prostagland Leukotr Essent Fatty Acids, 55, 71, 10.1016/S0952-3278(96)90148-9 · DOI · Paper page
- Pettegrew, 1991, Alterations in brain high energy phosphate and membrane phospholipid metabolism in first-episode, drug-naïve schizophrenics. A pilot study of dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy, Arch Gen Psychiatry, 48, 563, 10.1001/archpsyc.1991.01810300075011 · DOI · Paper page
- Reddy, 1996, Free radical pathology in schizophrenia, Prostagland Leukotr Essent Fatty Acids, 55, 33, 10.1016/S0952-3278(96)90143-X · DOI · Paper page
- Reddy, 1999, Essential fatty acids and outcome in first-episode schizophrenia, Schizophr Res, 36, 108
- Richardson, 2001, Association between central and peripheral measures of phospholipid breakdown revealed by cerebral 31-phosphorus magnetic resonance spectroscopy and fatty acid composition of erythrocyte membranes, Progr Neuropsychopharmacol Biol Psychiatry, 25, 1513, 10.1016/S0278-5846(01)00211-1 · DOI
- Stanley, 1994, Membrane phospholipid metabolism and schizophrenia, Schizophr Res, 13, 209, 10.1016/0920-9964(94)90044-2 · DOI
- Vaddadi, 1996, Dyskinesias and their treatment with EFAs, Prostagland Leukotr Essent Fatty Acids, 55, 89, 10.1016/S0952-3278(96)90151-9 · DOI
- Vaddadi, 1989, A double-blind trial of essential fatty acids supplementation in patients with tardive dyskinesia, Psychiatry Res, 27, 313, 10.1016/0165-1781(89)90146-7 · DOI
- Wainwright, 1992, Do essential fatty acids play a role in brain and behavioral development?, Neurosci Biobehavioral Rev, 16, 193, 10.1016/S0149-7634(05)80180-0 · DOI · Paper page
- Weinberger, 1987, Implications of normal brain development for the pathogenesis of schizophrenia, Arch Gen Psychiatry, 44, 660, 10.1001/archpsyc.1987.01800190080012 · DOI · Paper page
- 1973, Vol. 1
- Wyatt, 1997, Long-term morbidity associated with delayed treatment of admission schizophrenic patients, Psychol Med, 27, 261, 10.1017/S0033291796004345 · DOI
- Wyatt, 2001, Rationale for the study of early intervention, Schizophr Res, 51, 69, 10.1016/S0920-9964(01)00242-0 · DOI
- Yao, 2000, Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients, Schizophr Res, 42, 7, 10.1016/S0920-9964(99)00095-X · DOI · Paper page
- Yao, 1994, Red blood cell membrane dynamics II, Schizophr Res, 13, 217, 10.1016/0920-9964(94)90045-0 · DOI
- Yao, 1992, Increased turnover of platelet phosphatidylinositol in schizophrenia, Prostagland Leukotr Essent Fatty Acids, 46, 39, 10.1016/0952-3278(92)90057-P · DOI
Cited by
Oxidative stress in psychiatric disorders: evidence base and therapeutic implications
Ng, F., Berk, M., Dean, O., & Bush, A. I. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707008401 · Cited by 1,069
Vitamin C in Disease Prevention and Cure: An Overview
Chambial, S., Dwivedi, S., Shukla, K. K., John, P. J., & Sharma, P. (2013) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-013-0375-3 · Cited by 550
Meta-analysis of oxidative stress in schizophrenia.
Flatow, J., Buckley, P., & Miller, B. J. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.03.018 · Cited by 491
Ranjekar, P. K., Hinge, A., Hegde, M. V., Ghate, M., Kale, A., Sitasawad, S., Wagh, U. V., Debsikdar, V. B., & Mahadik, S. P. (2003) · Psychiatry Research · doi:10.1016/s0165-1781(03)00220-8 · Cited by 395
Self-citationAntioxidants, Redox Signaling, and Pathophysiology in Schizophrenia: An Integrative View
Yao, J. K., & Keshavan, M. S. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3603 · Cited by 285
Metadata
- Authors
- Arvindakshan, M., Sitasawad, S., Debsikdar, V., Ghate, M., Evans, D., Horrobin, D. F., Bennett, C., Ranjekar, P. K., & Mahadik, S. P.
- Venue
- Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2003-01
- Volume
- 53
- Issue
- 1
- Pages
- 56-64
- ISSN
- 0006-3223 (ISSN-L)
- OpenAlex
- W2020818277
- Cited by
- 232
- References
- 6
- FWCI
- 10.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. https://app.cochat.ai/papers/10.1016/s0006-3223(02)01443-9
- The paper
- Arvindakshan, M., Sitasawad, S., Debsikdar, V., Ghate, M., Evans, D., Horrobin, D. F., Bennett, C., Ranjekar, P. K., & Mahadik, S. P. (2003). Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biological Psychiatry. https://doi.org/10.1016/s0006-3223(02)01443-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.